vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $50.4M, roughly 1.4× Armour Residential REIT, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -49.0%, a 469.3% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 297.9%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ARR vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $70.6M |
| Net Profit | $211.7M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | 420.2% | -49.0% |
| Revenue YoY | 297.9% | 81958.1% |
| Net Profit YoY | 555.9% | 54.9% |
| EPS (diluted) | $2.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | — | ||
| Q3 25 | $38.5M | $70.6M | ||
| Q2 25 | $33.1M | — | ||
| Q1 25 | $36.3M | — | ||
| Q4 24 | $12.7M | — | ||
| Q2 24 | $7.0M | — | ||
| Q1 23 | $12.2M | — | ||
| Q4 22 | $11.6M | — |
| Q4 25 | $211.7M | — | ||
| Q3 25 | $159.3M | $-34.6M | ||
| Q2 25 | $-75.6M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $-46.4M | — | ||
| Q2 24 | $-48.4M | — | ||
| Q1 23 | $-31.4M | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | 420.2% | — | ||
| Q3 25 | 413.5% | -49.0% | ||
| Q2 25 | -228.4% | — | ||
| Q1 25 | 75.2% | — | ||
| Q4 24 | -366.8% | — | ||
| Q2 24 | -693.8% | — | ||
| Q1 23 | -256.8% | — | ||
| Q4 22 | — | — |
| Q4 25 | $2.43 | — | ||
| Q3 25 | $1.49 | — | ||
| Q2 25 | $-0.94 | — | ||
| Q1 25 | $0.32 | — | ||
| Q4 24 | $-0.91 | — | ||
| Q2 24 | $-1.05 | — | ||
| Q1 23 | $-0.95 | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $503.0M |
| Total Assets | $21.0B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | — | ||
| Q3 25 | $44.2M | $490.9M | ||
| Q2 25 | $141.2M | — | ||
| Q1 25 | $49.1M | — | ||
| Q4 24 | $68.0M | — | ||
| Q2 24 | $126.6M | — | ||
| Q1 23 | — | — | ||
| Q4 22 | $87.3M | — |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.1B | $503.0M | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.4B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 23 | $1.2B | — | ||
| Q4 22 | $1.1B | — |
| Q4 25 | $21.0B | — | ||
| Q3 25 | $19.4B | $577.1M | ||
| Q2 25 | $16.2B | — | ||
| Q1 25 | $15.5B | — | ||
| Q4 24 | $13.5B | — | ||
| Q2 24 | $10.1B | — | ||
| Q1 23 | $13.2B | — | ||
| Q4 22 | $9.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | — | ||
| Q3 25 | $-37.8M | $-84.6M | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $101.5M | — | ||
| Q4 24 | $261.5M | — | ||
| Q2 24 | $27.1M | — | ||
| Q1 23 | $54.2M | — | ||
| Q4 22 | $124.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
